Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commencement of dealings

19 Sep 2006 07:02

Quintessentially English PLC19 September 2006 QUINTESSENTIALLY ENGLISH PLC ("QE" OR THE "COMPANY") COMMENCEMENT OF DEALINGS Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC)announces that it has completed inter alia the acquisition of Omega DiagnosticsLimited, a £1 million placing of new ordinary shares and an issue of warrants toexisting shareholders in the Company. Its ordinary shares are due to bereadmitted to trading on AIM today. Highlights • Acquisition of Omega Diagnostics Limited, a UK company specialising in in-vitro diagnostics test kits and related products through a distribution network in more than 100 countries • £1 million new equity (before expenses) raised via a cash placing of 50,000,000 New Ordinary Shares at 2p per share • Issue of 5,588,432 QE Warrants to existing Shareholders to subscribe for Ordinary Shares at an exercise price of 2p per share • Appointment of a new management team from Omega Diagnostics Limited: Andrew Shepherd, Chief Executive, Kieron Harbinson, Finance Director, David Evans, Non-executive Chairman; Michael Gurner continues as a Non-executive Director • The Acquisition furthers Omega's strategy to become a leading in-vitro diagnostics company - its strategy is to grow through selective acquisitions Andrew Shepherd, Chief Executive, commented: "The purchase of Omega Diagnostics Limited continues our aim to acquirecompanies within the medical diagnostics sector and positions us as a key playerin the in-vitro diagnostics kit market. Our strategy is to grow by acquisitionand to build our portfolio of products which we are already distributingthroughout the UK and in over 100 countries worldwide." On completion, the Company will be paying a maximum consideration of £3 millionof which approximately £1.2 million will be satisfied by the issue of 60,600,000 New Ordinary Shares and the balance of up to approximately £1.8 million as deferred consideration to be satisfied by way of up to 89,400,000 Earn Out Shares at a minimum issue price of 2p per share subject to certain earn out targets being met for the financial year ending 31 March 2008. Immediately following admission, the issued share capital of the Company will be 121,776,865 Ordinary Shares. For further information, please contact: Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC) - 01259 763 030 Andrew ShepherdChief Executive Kieron HarbinsonFinance Director City Financial Associates Limited - 020 7090 7800 Barry SaintDirector END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Mar 20217:00 amRNSContract with Screen4
24th Feb 20217:00 amRNSUK-RTC statement on AbC-19TM rapid antibody test
19th Feb 20211:45 pmRNSDirector/PDMR Shareholding
18th Feb 202110:00 amRNSDirector/PDMR Shareholding
16th Feb 20217:00 amRNSAbC-19TM rapid antibody test performance data
15th Feb 20217:00 amRNSDirector/PDMR Shareholding
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:01 amRNSUK Government contract and trading update
11th Feb 20217:00 amRNSDirectorate Change
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSStatement re Media Comment
2nd Feb 20218:45 amRNSExercise of Options and Total Voting Rights
28th Jan 20211:15 pmRNSExercise of Options and Total Voting Rights
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
26th Jan 20217:02 amRNSLab-based COVID-19 antibody test service launch
26th Jan 20217:01 amRNSUpdate re AbC-19 Rapid Test
25th Jan 202111:06 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
22nd Jan 202110:15 amRNSExercise of Options and Total Voting Rights
22nd Jan 20219:05 amRNSSecond Price Monitoring Extn
22nd Jan 20219:00 amRNSPrice Monitoring Extension
11th Jan 202111:00 amRNSExercise of Options and Total Voting Rights
29th Dec 20207:01 amRNSUpdate re AbC-19 Rapid Test
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
24th Dec 202012:41 pmRNSSecond Price Monitoring Extn
24th Dec 202012:35 pmRNSPrice Monitoring Extension
24th Dec 202012:00 pmRNSMologic CE Mark Rapid Antigen Test
24th Dec 202011:05 amRNSSecond Price Monitoring Extn
24th Dec 202011:00 amRNSPrice Monitoring Extension
11th Dec 20202:05 pmRNSSecond Price Monitoring Extn
11th Dec 20202:00 pmRNSPrice Monitoring Extension
11th Dec 20209:45 amRNSExercise of Options and Total Voting Rights
7th Dec 20208:00 amRNSExercise of Options and Total Voting Rights
2nd Dec 20209:00 amRNSDirector/PDMR Shareholding
30th Nov 20202:30 pmRNSExercise of Options and Total Voting Rights
30th Nov 20207:00 amRNSInterim Results
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:01 pmRNSPrice Monitoring Extension
23rd Nov 20209:45 amRNSExercise of Options and Total Voting Rights
17th Nov 20207:45 amRNSUK-RTC Update
16th Nov 20207:16 amRNSHolding(s) in Company
16th Nov 20207:15 amRNSHolding(s) in Company
13th Nov 20202:05 pmRNSSecond Price Monitoring Extn
13th Nov 20202:00 pmRNSPrice Monitoring Extension
13th Nov 20209:30 amRNSExercise of Options and Total Voting Rights
12th Nov 20203:42 pmRNSUK-RTC Statement
12th Nov 202011:05 amRNSSecond Price Monitoring Extn
12th Nov 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.